Traws Pharma, Inc. TRAW
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -73.81%
- 1 year
- -88.79%
- Open
- 0.3098
- Prev close
- 0.301
- Mkt cap
- 4.55M
- Vol
- 199.52K
- Avg vol
- 582.99K
- EPS
- -1.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2876
- High
- 0.3098
- Forward P/E
- -0.47
- Beta
- 1.41
- Short ratio
- 0.62
- Inst. own
- 21.40%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.96
- 200-d avg
- 11.13
- 1y target
- 6.00
News
-
6 days ago benzinga.com
Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock
Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments"…
1 month ago defenseworld.net
Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)
Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) and Traws Pharma (NASDAQ: TRAW - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million. Firefly Neuroscience…
1 month ago benzinga.com
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.
-
2 months ago benzinga.com
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of…
2 months ago globenewswire.com
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to…
2 months ago defenseworld.net
Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $0.4871 and last traded at $0.4716. Approximately 94,244 shares…
-
4 months ago benzinga.com
Traws PharmaFiles Prospectus For Mixed Shelf Offering Of Up To ~$139.2M
Traws Pharma, Inc. $139,185,641.25 Common StockPreferred StockDebt SecuritiesWarrantsUnits This prospectus covers our offer and sale from time to time of any combination of common stock, preferred…
-
4 months ago benzinga.com
Traws Pharma Announces That An Updated Toxicology Data Package Is Being Developed In Response To The UK MHRA's Information Requirements For Planned Testing Of Tivoxavir Marboxil In A Phase 2a Human Influenza Challenge Study
The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. "Based upon recent feedback and further guidance from the MHRA, we believe our updated data package…
4 months ago globenewswire.com
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to…
4 months ago benzinga.com
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
-
4 months ago benzinga.com
HC Wainwright & Co. Downgrades Traws Pharma to Neutral, Announces $1 Price Target
HC Wainwright & Co. analyst Brandon Folkes downgrades Traws Pharma (NASDAQ:TRAW) from Buy to Neutral and announces $1 price target.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
4 months ago benzinga.com
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
4 months ago benzinga.com
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxavir marboxil, delaying clinical development.
-
4 months ago benzinga.com
10 Health Care Stocks Moving In Monday's Pre-Market Session
10 Health Care Stocks Moving In Monday's Pre-Market Session
4 months ago benzinga.com
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining in pre-market trading.
4 months ago benzinga.com
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply agreement and resolving IP disputes. Other gainers include VS Media Holdings (VSME), Freecast Inc…
4 months ago globenewswire.com
Traws Pharma Provides Regulatory Update on Influenza Program
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral…
-
4 months ago benzinga.com
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
-
5 months ago benzinga.com
Traws Pharma Announces Advancement Of Its Novel Proprietary Broad-Spectrum Combination Anti-Viral Agent With Potential Utility Against Hantavirus, Ebola and Lassa
Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced the advancement of a novel proprietary…
5 months ago globenewswire.com
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Traws Pharma, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Buy and maintains $8 price target.
-
5 months ago benzinga.com
Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 66.46 percent increase over losses of $(1.58)…
5 months ago globenewswire.com
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
5 months ago benzinga.com
Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World
Hantavirus outbreak on a cruise ship sparks alarm as Schumer blames CDC cuts, warning weakened disease surveillance and calling for urgent reforms.
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
5 months ago benzinga.com
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.
5 months ago benzinga.com
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
Traws Pharma shares jump after the company advanced hantavirus antiviral candidates amid global monitoring of a cruise ship outbreak.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
5 months ago benzinga.com
Traws Pharma Announces Plans To Advance Potential Clinical Candidates For The Treatment Of Hantavirus Infection
Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from…
5 months ago globenewswire.com
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
6 months ago zacks.com
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement…
6 months ago seekingalpha.com
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
6 months ago globenewswire.com
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
6 months ago defenseworld.net
Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy?
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high as $1.64 and last traded at $1.61. 21,635 shares were traded during trading, a decline of 60% from…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
8 months ago globenewswire.com
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution;…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
9 months ago globenewswire.com
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 months ago benzinga.com
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday